Epigenetics Drugs & Diagnostic Technologies Market Share,Size and Forecast 2019-2026

SKU: DHC267 | Last Updated On: 2019-08-16 | No. of Pages: 201 | Available Formats

( 31 Samples have been requested. )
In March 2019, Celeron Therapeutics announced a new Phase Ib/II clinical trial testing of a new immune-oncology agent combined with epigenetic regulator CXD101.

Global Epigenetics Drugs & Diagnostic Technologies Market Overview

The global Epigenetics Drugs & Diagnostic Technologies market was worth US $ billion in 2018 and is forecasted to reach US$ billion by 2026, at a CAGR of % during the forecast period.

Epigenetics is a process of changing the gene expression; it's a phenotype change without a change in genotype. The essential parts that are engaged with epigenetic interpretation are DNA methylation, histone changes, and non-coding RNA’s. Epigenetics drugs and diagnostic technologies are used in the screening of early-stage cancer and other abnormal changes in liver cells, brain cells, skin cells, and others. With the rising awareness among people and rising incidences & prevalence of oncology and non-oncology disorders, the interest for epigenetic analysis and medications is growing at a high pace and boosting the global epigenetics drugs and diagnostics technologies market.

Global Epigenetics Drugs & Diagnostic Technologies Market – Market Dynamics

Rising prevalence of cancer and other chronic diseases along with growing geriatric population are the major factors driving the global epigenetics drugs & diagnostic technologies market. According to WHO, in 2018, there are an estimation of 18.1 million new cancer cases and 9.6 million deaths, about 1 in 6 deaths are due to cancer. Thus, growing cancer incidences are boosting the market growth.

Also, funding’s by government organizations such as the National Cancer Institute (NCI), the International Human Epigenome Consortium (IHEC), and the National Institute of Health (NIH) to promote R&D activities is anticipated to propel the global epigenetics drugs & diagnostics market further. Further, increased attention of manufacturers towards the development of new epigenetics drugs is boosting the market growth.

Global Epigenetics Drugs & Diagnostic Technologies Market – Segment Analysis

Based on product, the global Epigenetics Drugs & Diagnostic Technologies market is broadly segmented as oncology and non-oncology segment. Oncology application segment accounted for major market share in 2018, owing to the growing prevalence of cancer. However, over the forecast period, non-oncology application segment is expected to grow at a high pace. It is due to R&D initiatives undertaken by private institutions and biopharmaceutical companies for identification of epigenetic markers related to non-oncology disorders. Non-oncology disorders include cardiovascular, infectious, and other disorders. Epigenetic modifications have been proved to be the base of metabolic, infectious diseases, neurodegenerative, and many other non-oncology disorders. Thus, growing non-oncology disorder segment is driving the global market.

Global Epigenetics Drugs & Diagnostic Technologies Market – Geographical Analysis

The global Epigenetics Drugs & Diagnostic Technologies market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.  North America region accounted for major market share in 2018, in the global epigenetics drugs & diagnostics technologies market. Presence of government funding programs for ongoing research activities, better healthcare facilities, and continuously increasing incidences of oncology and non-oncology diseases including metabolic, infectious, cardiovascular, and other diseases.

During the forecast period (2019-2026), the Asia Pacific region is projected to grow at a significant rate, owing to the rising disposable income, rising awareness about early diagnosis, and availability of effective treatment in emerging countries, such as India and China. Additionally, due to increasing cases of various types of cancers. Also, due to the presence of prominent players of the market, such as Eisai Pharmaceuticals and Oncolys Biopharma.

Global Epigenetics Drugs & Diagnostic Technologies Market – Competitive Analysis

Significant players of the global epigenetics drugs & diagnostic technologies market are Thermo Fisher Scientific., Merck & Company Inc., Novartis International AG, Astex Pharmaceuticals Inc., Celenge, CellCentric Ltd., Celeron Therapeutics Ltd., Chroma Therapeutics Ltd., Eisai Pharmaceuticals, Epigentek Group Inc., and others. The diversified product portfolio is the major factor that is responsible for strengthening the position of these companies in the market. Also, they have been adopting key strategies, such as new product developments, acquisitions, and expansions, to increase their share in the epigenetics drugs & diagnostics market. For instance, in

  • In January 2018, Thermo Fisher Scientific collaborated with Illumina, Inc. to sell Ion AmpliSeq technology to researchers who conduct scientific studies on Illumina’s next-generation sequencing (NGS) platforms.
  • In August 2017, BellBrook Labs announced the launch of AptaFluor SAH Methyltransferase Assay, to help researchers in their research for breakthrough drugs targeting epigenetic pathways that drive cancer and other debilitating diseases.
  • In May 2017, Merck developed alternative genome editing tool that makes CRISPR more efficient, flexible, and specific.
  • In October 2015, Celgene’s VIDAZA® was approved by the European Commission(EC).
  • In April 2015, Roche and Oryzon collaborated to develop and commercialize LSD1 inhibitors for oncology, and non-malignant conditions

Why Purchase the Report?

  • Visualize the composition of the Epigenetics Drugs & Diagnostic Technologies market across each indication, in terms of type and treatment options, highlighting the key commercial assets and players.
  • Identify commercial opportunities in the Epigenetics Drugs & Diagnostic Technologies market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the Epigenetics Drugs & Diagnostic Technologies market - level 4/5 segmentation.
  • A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key products of all major market players

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
  1. Global  Epigenetics Drugs & Diagnostic Technologies Market Methodology and Scope
    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Global  Epigenetics Drugs & Diagnostic Technologies Market – Market Definition and Overview
  3. Global  Epigenetics Drugs & Diagnostic Technologies Market – Executive Summary
    1. Market Snippet by Technology
    2. Market Snippet by Application
    3. Market Snippet by Region     

 Global  Epigenetics Drugs & Diagnostic Technologies Market – Market Dynamics

    1. Market Impacting Factors
      1. Drivers
        1. Rising prevalence of cancer and other chronic diseases
        2. Funding’s by Government Organizations
      2. Restraints
      3. Opportunity
      4. Impact Analysis
  1. Global  Epigenetics Drugs & Diagnostic Technologies Market – Industry Analysis
    1. Porter's Five Forces Analysis
    2. Supply Chain Analysis
    3. Pricing Analysis
    4. Regulatory Analysis
    5. Patent Analysis
  2. Global  Epigenetics Drugs & Diagnostic Technologies Market – By Technology
      1.  Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
      3. Market Attractiveness Index, By Technology
    1. DNA Methylation
      1. Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
    2. Chromatin Immunoprecipitation (ChIP) Technology
    3. Histone Methylation
    4. MicroRNA Modification
    5. Others
  3. Global  Epigenetics Drugs & Diagnostic Technologies Market – By Application
      1.  Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
      3. Market Attractiveness Index, By Application
    1. Oncology
      1. Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
    2. Non-Oncology
      1. Inflammatory Diseases
      2. Cardiovascular Diseases
      3. Infectious Diseases       
  4. Global  Epigenetics Drugs & Diagnostic Technologies Market – By Region
    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. The U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. The U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. Middle East & Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  5. Global Epigenetics Drugs & Diagnostic Technologies Market – Competitive Landscape
    1.   Competitive Scenario
    2.  Competitor  Epigenetics Drugs & Diagnostic Technologies Strategy Analysis
    3. Comparative Technology Portfolio Analysis
    4. Market Positioning/Share Analysis
    5. Mergers and Acquisitions Analysis
  6. Global Epigenetics Drugs & Diagnostic Technologies Market - Company Profiles
    1. Thermo Fisher Scientific.
      1. Company Overview
      2. Technology Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Merck & Company, Inc.
    3. Novartis International AG
    4. Astex Pharmaceuticals Inc.
    5. Celenge
    6. CellCentric Ltd.
    7.  Celeron Therapeutics Ltd.
    8.  Chroma Therapeutics Ltd.
    9. Eisai Pharmaceuticals
    10.  Epigentek Group Inc
  7. Global  Epigenetics Drugs & Diagnostic Technologies Market – Premium Insights
  8. Global  Epigenetics Drugs & Diagnostic Technologies Market – DataM
    1. Appendix
    2. About Us and Services
    3. Contact Us

LIST  OF  TABLES
TABLE  01.  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  2018,  2022  &  2026,  BY  TECHNOLOGY,  ($MILLION)
TABLE  02.  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE  2018,  2022  &  2026,  BY  APPLICATION,  ($MILLION)
TABLE  03.  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE  2018,  2022  &  2026,  BY  REGION,  ($MILLION)
TABLE  04.  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  2018,  2022  &  2026  (%),  BY  TECHNOLOGY  ($MILLION)
TABLE  05.  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  TECHNOLOGY,  2018–2026  ($MILLION)
TABLE  06.  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  2018,  2022  &  2026  (%),  BY  APPLICATION  ($MILLION)
TABLE  07.  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  APPLICATION,  2018–2026  ($MILLION)
TABLE  08.  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  2018,  2022  &  2026  (%),  BY  REGION  ($MILLION)
TABLE  09.  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  REGION,  2018–2026  ($MILLION)
TABLE  10.  NORTH  AMERICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  TECHNOLOGY,  2018–2026  ($MILLION)
TABLE  11.  NORTH  AMERICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  APPLICATION,  2018–2026  ($MILLION)
TABLE  12.  NORTH  AMERICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  COUNTRY,  2018–2026  ($MILLION)

TABLE  13.  SOUTH  AMERICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  TECHNOLOGY,  2018–2026  ($MILLION)
TABLE  14.  SOUTH  AMERICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  APPLICATION,  2018–2026  ($MILLION)
TABLE  15.  SOUTH  AMERICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  COUNTRY,  2018–2026  ($MILLION)
TABLE  16.  EUROPE  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  TECHNOLOGY,  2018–2026  ($MILLION)
TABLE  17.  EUROPE  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  APPLICATION,  2018–2026  ($MILLION)
TABLE  18.  EUROPE  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  COUNTRY,  2018–2026  ($MILLION)
TABLE  19.  ASIA  PACIFIC  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  TECHNOLOGY,  2018–2026  ($MILLION)
TABLE  20.  ASIA  PACIFIC  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  APPLICATION,  2018–2026  ($MILLION)
TABLE  21.  ASIA  PACIFIC  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  COUNTRY,  2018–2026  ($MILLION)
TABLE  22.  MIDDLE  EAST  &  AFRICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  TECHNOLOGY,  2018–2026  ($MILLION)
TABLE  23.  MIDDLE  EAST  &  AFRICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  APPLICATION,  2018–2026  ($MILLION)
TABLE  24.  THERMO  FISHER  SCIENTIFIC.:  OVERVIEW
TABLE  25.  THERMO  FISHER  SCIENTIFIC.:  TECHNOLOGY  PORTFOLIO
TABLE  26.  THERMO  FISHER  SCIENTIFIC.:  KEY  DEVELOPMENTS
TABLE  27.  MERCK  &  COMPANY  INC:  OVERVIEW
TABLE  28.  MERCK  &  COMPANY  INC:  TECHNOLOGY  PORTFOLIO
TABLE  29.  MERCK  &  COMPANY  INC:  KEY  DEVELOPMENTS
TABLE  30.  NOVARTIS  INTERNATIONAL  AG:  OVERVIEW
TABLE  31.  NOVARTIS  INTERNATIONAL  AG:  TECHNOLOGY  PORTFOLIO
TABLE  32.  NOVARTIS  INTERNATIONAL  AG:  KEY  DEVELOPMENTS
TABLE  33.  ASTEX  PHARMACEUTICALS  INC:  OVERVIEW
TABLE  34.  ASTEX  PHARMACEUTICALS  INC:  TECHNOLOGY  PORTFOLIO
TABLE  35.  ASTEX  PHARMACEUTICALS  INC:  KEY  DEVELOPMENTS
TABLE  36.  CELENGE.:  OVERVIEW
TABLE  37.  CELENGE.:  TECHNOLOGY  PORTFOLIO
TABLE  38.  CELENGE.:  KEY  DEVELOPMENTS
TABLE  39.  CELLCENTRIC  LTD:  OVERVIEW
TABLE  40.  CELLCENTRIC  LTD:  TECHNOLOGY  PORTFOLIO
TABLE  41.  CELLCENTRIC  LTD:  KEY  DEVELOPMENTS
TABLE  42.  CELERON  THERAPEUTICS  LTD.:  OVERVIEW
TABLE  43.  CELERON  THERAPEUTICS  LTD.:  TECHNOLOGY  PORTFOLIO
TABLE  44.  CELERON  THERAPEUTICS  LTD.:  KG:  KEY  DEVELOPMENTS
TABLE  45.  CHROMA  THERAPEUTICS  LTD.:  OVERVIEW
TABLE  46.  CHROMA  THERAPEUTICS  LTD.:  TECHNOLOGY  PORTFOLIO
TABLE  47.  CHROMA  THERAPEUTICS  LTD.:  KEY  DEVELOPMENTS
TABLE  48.  EISAI  PHARMACEUTICALS:  OVERVIEW
TABLE  49.  EISAI  PHARMACEUTICALS:  TECHNOLOGY  PORTFOLIO
TABLE  50.  EISAI  PHARMACEUTICALS:  KEY  DEVELOPMENTS
TABLE  51.  EPIGENTEK  GROUP  INC:  OVERVIEW
TABLE  52.  EPIGENTEK  GROUP  INC:  TECHNOLOGY  PORTFOLIO
TABLE  53.  EPIGENTEK  GROUP  INC:  KEY  DEVELOPMENTS

LIST  OF  FIGURES
FIGURE  01.  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE,  2018  &  2026  (%),  BY  TECHNOLOGY
FIGURE  02.  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE,  2018  &  2026  (%),  BY  APPLICATION
FIGURE  03.  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE,  2018  &  2026  (%),  BY  REGION
FIGURE  04.  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  2018  -  2026  AND  YEAR  ON  YEAR  GROWTH
FIGURE  05.  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  YEAR  ON  YEAR  GROWTH  2018  TO  2026  (%),  BY  TECHNOLOGY  
FIGURE  06    GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  DNA  METHYLATION,  2018–2026  ($MILLION)
FIGURE  07    GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  CHROMATIN  IMMUNOPRECIPITATION  (CHIP)  TECHNOLOGY,  2018–2026  ($MILLION)
FIGURE  08    GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  HISTONE  METHYLATION,  2018–2026  ($MILLION)
FIGURE  09    GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  MicroRNA  Modification,  2018–2026  ($MILLION)
FIGURE  10    GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  OTHERS,  2018–2026  ($MILLION)
FIGURE  11      GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  YEAR  ON  YEAR  GROWTH  2018  TO  2026  (%),  BY  APPLICATION
FIGURE  12    GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  ONCOLOGY,  2018–2026  ($MILLION)
FIGURE  13    GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  BY  NON-ONCOLOGY,  2018–2026  ($MILLION)
FIGURE  14  GLOBAL  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  YEAR  ON  YEAR  GROWTH  2018  TO  2026  (%),  BY  REGION
FIGURE  15    NORTH  AMERICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  2018–2026  ($MILLION)
FIGURE  16    NORTH  AMERICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  (%),  BY  TECHNOLOGY,  2018–2026  ($MILLION)
FIGURE  17    NORTH  AMERICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  (%),  BY  APPLICATION,  2018–2026  ($MILLION)
FIGURE  18    NORTH  AMERICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  (%),  BY  COUNTRIES,  2018–2026  ($MILLION)  
FIGURE  19  SOUTH  AMERICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  2018–2026  ($MILLION)
FIGURE  20    SOUTH  AMERICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  (%),  BY  TECHNOLOGY,  2018–2026  ($MILLION)
FIGURE  21  SOUTH  AMERICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  (%),  BY  APPLICATION,  2018–2026  ($MILLION)
FIGURE  22    SOUTH  AMERICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  (%),  BY  COUNTRIES,  2018–2026  ($MILLION)

FIGURE  23    EUROPE  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  2018–2026  ($MILLION)
FIGURE  24  EUROPE  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  (%),  BY  TECHNOLOGY,  2018–2026  ($MILLION)
FIGURE  25    EUROPE  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  (%),  BY  APPLICATION,  2018–2026  ($MILLION)
FIGURE  26  EUROPE  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  (%),  BY  COUNTRIES,  2018–2026  ($MILLION)
FIGURE  27      ASIA  PACIFIC  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  2018–2026  ($MILLION)
FIGURE  28    ASIA  PACIFIC  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  (%),  BY  TECHNOLOGY,  2018–2026  ($MILLION)
FIGURE  29    ASIA  PACIFIC  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  (%),  BY  APPLICATION,  2018–2026  ($MILLION)
FIGURE  30    ASIA  PACIFIC  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  (%),  BY  COUNTRIES,  2018–2026  ($MILLION)
FIGURE  31  MIDDLE  EAST  AND  AFRICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  VALUE,  2018–2026  ($MILLION)
FIGURE  32    MIDDLE  EAST  AND  AFRICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  (%),  BY  TECHNOLOGY,  2018–2026  ($MILLION)
FIGURE  33    MIDDLE  EAST  AND  AFRICA  EPIGENETICS  DRUGS  &  DIAGNOSTIC  TECHNOLOGIES  MARKET  SHARE  (%),  BY  APPLICATION,  2018–2026  ($MILLION)
FIGURE  34.  THERMO  FISHER  SCIENTIFIC.:  FINANCIALS
FIGURE  35.  MERCK  &  COMPANY  INC:  FINANCIALS
FIGURE  36.  NOVARTIS  INTERNATIONAL  AG:  FINANCIALS
FIGURE  37  ASTEX  PHARMACEUTICALS  INC:  FINANCIALS
FIGURE  38.  CELENGE.:  FINANCIALS
FIGURE  39.  CELLCENTRIC  LTD:  FINANCIALS
FIGURE  40.    CELLERON  THERAPEUTICS  LTD.:  FINANCIALS
FIGURE  41.  CHROMA  THERAPEUTICS  LTD.:  FINANCIALS
FIGURE  42.  EISAI  PHARMACEUTICALS:  FINANCIALS
FIGURE  43.  EPIGENTEK  GROUP  INC:  FINANCIALS
 

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
step 1We collate your requirements.
step 2Our global research team is put into action.
step 3We deliver, and make sure your endeavour is a success!

Buy This Report